论文部分内容阅读
目的研究早期宫颈癌微淋巴转移病理与临床关系。方法早期宫颈癌患者44例,采用资料回顾性分析方法 ,研究标本中D2-40、CD105以及VEGF-C在各个宫颈癌临床分期中的表达情况。结果经分期研究,D2-40在0期患者中微淋巴管密度(LMVD)计数为(7.58±1.92)个、Ⅰ期的LMVD计数为(7.06±2.44)个、Ⅱ期的LMVD计数为(5.56±2.43)个;CD105在0期患者中血管密度(MVD)计数为(7.51±1.02)个、Ⅰ期的MVD计数为(8.06±3.91)个、Ⅱ期的MVD计数为(8.72±3.49)个;VEGF-C在0期(+)2例,占20.00%,VEGF-C在Ⅰ期17例,占85.00%,VEGF-C在Ⅱ期9例,占90.00%。结论 D2-40、CD105以及VEGF-C在各个宫颈癌临床分期中的表达显示,其对于宫颈癌患者进行临床诊断具有非常重要的指导意义,值得临床的应用和推广。
Objective To study the pathological and clinical relationship between lymphatic metastasis of early cervical cancer. Methods Forty-four patients with early stage cervical cancer were studied retrospectively. Data of D2-40, CD105 and VEGF-C in clinical stages of cervical cancer were analyzed. Results According to staging study, the number of LMVD in stage D2-40 was (7.58 ± 1.92), the stage Ⅰ LMVD was (7.06 ± 2.44), the stage Ⅱ LMVD was (5.56 ± 2.43). The number of MVD in CD105 was (7.51 ± 1.02) in stage 0, the MVD in stage Ⅰ was (8.06 ± 3.91), the MVD in stage Ⅱ was (8.72 ± 3.49) ; VEGF-C in stage 0 (+) 2 cases, accounting for 20.00%, VEGF-C in stage I 17 cases, 85.00%, VEGF-C in stage 9 9 cases, accounting for 90.00%. Conclusions The expressions of D2-40, CD105 and VEGF-C in clinical stages of cervical cancer show that they have very important guiding significance for the clinical diagnosis of cervical cancer patients, which is worthy of clinical application and promotion.